25 min listen
NEJM Interview: Dr. James Robinson on the aducanumab experience and the structural factors responsible for high drug prices in the United States.
FromNEJM Interviews
NEJM Interview: Dr. James Robinson on the aducanumab experience and the structural factors responsible for high drug prices in the United States.
FromNEJM Interviews
ratings:
Length:
11 minutes
Released:
Nov 24, 2021
Format:
Podcast episode
Description
Dr. James Robinson is a professor of health economics at the University of California, Berkeley, School of Public Health. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. J.C. Robinson. Why Is Aducanumab Priced at $56,000 per Patient? Lessons for Drug-Pricing Reform. N Engl J Med 2021;385:2017-2019.
Released:
Nov 24, 2021
Format:
Podcast episode
Titles in the series (100)
NEJM Interview: Dr. Howard Brody on the ethics of rationing and waste avoidance in health care. by NEJM Interviews